drugset / Trial / NCT00957853

Preoperative Treatment With Cetuximab and/or IMC-A12

NCT00957853

RandomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to give cetuximab and/or IMC-A12 before surgery for squamous cell carcinoma of the head and neck, in order to learn if these study drugs may cause changes in biomarkers. Biomarkers are chemical "markers" in the blood and/or tissue that may be related to a reaction to study treatment. The safety of the study treatments will also be studied.

Timeline

Start
2011-10-17
Primary completion
2018-08-15
Completion
2018-08-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetuximab Monoclonal antibody 250 mg/m2 Intravenous
Subject Cixutumumab Monoclonal antibody 6 mg/kg Intravenous